Nipro PharmaPackaging’s Direct-to-Fill glass vials. Credit: © 2024 Nipro Europe Group Companies.

Nipro PharmaPackaging, a provider of glass tubing, glass primary packaging, and medical devices, has launched its Direct-to-Fill (D2F) glass vials.  

These vials incorporate Stevanato Group’s advanced EZ-fill technology, providing a ready-to-use solution that meets the stringent demands and growing needs of the pharmaceutical sector. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The D2F glass vials are washed, depyrogenated, packaged in nest and tub formats, and sterilised.  

In addition, these vials can be directly integrated into aseptic fill-finish processes, enhancing operational efficiency. 

Developed in partnership with leading machine suppliers, the D2F vials are also compatible with a diverse array of fill-finish lines.  

See Also:

This compatibility ensures quick and easy integration into existing systems, which can significantly accelerate production timelines. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The design of D2F vials, featuring a nest and tub configuration, minimises glass-to-glass contact, according to Nipro.  

This reduces the risk of breakage, cosmetic defects, and particle generation during transport and handling.  

The result is a product with improved mechanical durability, reduced downtime, and fewer rejections during quality inspections, which can lead to more stable and cost-effective fill-finish operations. 

Nipro PharmaPackaging CEO Stephan Arnold said: “We are excited to introduce D2F glass vials, offering a reliable and efficient RTU packaging solution that addresses the evolving needs of the pharmaceutical industry. 

“These vials exemplify our mission to delivering trust with premium primary pharma packaging solutions.” 

Nipro PharmaPackaging, a part of Nipro Corporation Japan, specialises in developing and manufacturing advanced pharmaceutical packaging products and complete packaging solutions. 

The company serves both early-stage drug development and the enhancement of packaging for existing pharmaceutical drugs.